PriceTargets.com logo

IceCure Medical - ICCM Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $62.70
  • Forecasted Upside: 2,069.55%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.89 As of 07/31/2026 05:00 PM ET
+0 (0.00%)

This chart shows the closing price for ICCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IceCure Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICCM

Analyst Price Target is $62.70
▲ +2,069.55% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for IceCure Medical in the last 3 months. The average price target is $62.70, with a high forecast of $83.10 and a low forecast of $30.00. The average price target represents a 2,069.55% upside from the last price of $2.89.

This chart shows the closing price for ICCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in IceCure Medical. This rating has held steady since October 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/2/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/1/2026

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/17/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
5/14/2026Maxim GroupLower TargetBuy ➝ Buy$90.00 ➝ $30.00
5/4/2026Alliance Global PartnersInitiated CoverageBuy ➝ Buy
4/21/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
1/22/2026Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/7/2025HC WainwrightBoost TargetBuy ➝ Buy$60.00 ➝ $75.00
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/15/2025HC WainwrightLower TargetBuy ➝ Buy$75.00 ➝ $60.00
8/15/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
8/13/2025Loop CapitalSet Target$83.10
5/29/2025HC WainwrightReiterated RatingBuy ➝ Buy$75.00
3/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
11/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
11/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
11/1/2024Alliance Global PartnersUpgradeStrong-Buy
9/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
8/21/2024HC WainwrightLower TargetBuy ➝ Buy$90.00 ➝ $75.00
7/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
6/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
5/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
4/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
4/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
3/20/2024Alliance Global PartnersBoost TargetBuy ➝ Buy$57.00 ➝ $87.00
3/20/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
3/5/2024HC WainwrightReiterated RatingBuy ➝ Buy$90.00
11/29/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00
9/6/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00
8/15/2023Alliance Global PartnersLower TargetBuy ➝ Buy$127.50 ➝ $120.00
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00
7/25/2023HC WainwrightReiterated RatingBuy ➝ Buy$90.00
3/28/2023HC WainwrightReiterated RatingBuy$90.00
3/20/2023HC WainwrightReiterated RatingBuy
10/25/2022Maxim GroupInitiated CoverageBuy$90.00
5/19/2022Alliance Global PartnersLower TargetBuy ➝ Buy$285.00 ➝ $172.50
1/14/2022Alliance Global PartnersLower Target$435.00 ➝ $285.00
9/22/2021Alliance Global PartnersInitiated CoverageBuy$435.00
(Data available from 8/2/2021 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/3/2026
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/2/2026
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
3/4/2026
  • 0 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2026
  • 2 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2026

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
IceCure Medical logo
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Read More

Today's Range

Now: $2.89
Low: $2.80
High: $3.09

50 Day Range

MA: $4.47
Low: $2.13
High: $9.30

52 Week Range

Now: $2.89
Low: $2.12
High: $42.00

Volume

53,297 shs

Average Volume

172,853 shs

Market Capitalization

$9.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43

Frequently Asked Questions

What sell-side analysts currently cover shares of IceCure Medical?

The following Wall Street sell-side analysts have issued reports on IceCure Medical in the last twelve months: Alliance Global Partners, HC Wainwright, Loop Capital, Maxim Group, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for ICCM.

What is the current price target for IceCure Medical?

0 Wall Street analysts have set twelve-month price targets for IceCure Medical in the last year. Their average twelve-month price target is $62.70, suggesting a possible upside of 2,069.6%. Loop Capital has the highest price target set, predicting ICCM will reach $83.10 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $30.00 for IceCure Medical in the next year.
View the latest price targets for ICCM.

What is the current consensus analyst rating for IceCure Medical?

IceCure Medical currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ICCM, but not buy more shares or sell existing shares.
View the latest ratings for ICCM.

What other companies compete with IceCure Medical?

Other companies that are similar to IceCure Medical include Milestone Scientific, Nephros, QT Imaging, Nutriband and Inspira Technologies OXY B.H.N.. Learn More about companies similar to IceCure Medical.

How do I contact IceCure Medical's investor relations team?

The company's listed phone number is 972-4623-0333 and its investor relations email address is [email protected]. The official website for IceCure Medical is www.icecure-medical.com. Learn More about contacing IceCure Medical investor relations.